ABCG2 and diffuse large B-cell lymphoma: Furthermore, they demonstrated that the upregulation or inhibition of the hedgehog (Hh) signaling pathway, a key factor behind the expression of BRCP/ABCG2, may present a therapeutic target in overcoming chemoresistance in DLBCL.